Abbott Laboratories (ABT) said Monday new results from a trial showed that the TriClip transcatheter edge-to-edge repair system to treat leaky heart valves provided "substantial and sustained improvements" in the severity of the condition after two years.
The data also showed that that the device significantly reduced the rate of heart failure hospitalizations and improved the quality of life of patients, the company said.
Abbott shares were slightly higher in recent trading.
Price: 131.81, Change: +0.99, Percent Change: +0.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.